Toxicity evaluation of ConvitVax breast cancer immunotherapy

Abstract ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin. Previous pre-clinical studies show that this therapy induces a potent activation of the immune system and achieves a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	María A. Duarte C., Jeismar M. Carballo O., Yetsenia M. De Gouveia, Angie García, Diana Ruiz, Teresa Gledhill, Eglys González-Marcano, Ana F. Convit
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/461a597176ad4ecb8e80b3aeab115e68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:461a597176ad4ecb8e80b3aeab115e68
record_format	dspace
spelling	oai:doaj.org-article:461a597176ad4ecb8e80b3aeab115e682021-12-02T17:41:10ZToxicity evaluation of ConvitVax breast cancer immunotherapy10.1038/s41598-021-91995-62045-2322https://doaj.org/article/461a597176ad4ecb8e80b3aeab115e682021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91995-6https://doaj.org/toc/2045-2322Abstract ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin. Previous pre-clinical studies show that this therapy induces a potent activation of the immune system and achieves an effective response against tumor cells, reducing the size of the tumor and decreasing the percentage of immunosuppressive cells. In the present study, we evaluate the toxicity of ConvitVax in healthy BALB/c mice to determine potential adverse effects related to the vaccine and each of its components. We used standard guidelines for pain, discomfort and distress recognition, continuously evaluated the site of the injection, and completed blood and urine clinical tests. Endpoint necropsy was performed, measuring the weight of organs and processing liver, kidney, thymus and lung for histological examination. Results show that the vaccine in its therapeutic dose, at 3 times its therapeutic concentration, and its individual components did not cause death or behavioral or biological changes, including any abnormalities in whole-body or organ weights, and tissue damage. These results support the safety of ConvitVax with minimal to no side-effects.María A. Duarte C.Jeismar M. Carballo O.Yetsenia M. De GouveiaAngie GarcíaDiana RuizTeresa GledhillEglys González-MarcanoAna F. ConvitNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q María A. Duarte C. Jeismar M. Carballo O. Yetsenia M. De Gouveia Angie García Diana Ruiz Teresa Gledhill Eglys González-Marcano Ana F. Convit Toxicity evaluation of ConvitVax breast cancer immunotherapy
description	Abstract ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin. Previous pre-clinical studies show that this therapy induces a potent activation of the immune system and achieves an effective response against tumor cells, reducing the size of the tumor and decreasing the percentage of immunosuppressive cells. In the present study, we evaluate the toxicity of ConvitVax in healthy BALB/c mice to determine potential adverse effects related to the vaccine and each of its components. We used standard guidelines for pain, discomfort and distress recognition, continuously evaluated the site of the injection, and completed blood and urine clinical tests. Endpoint necropsy was performed, measuring the weight of organs and processing liver, kidney, thymus and lung for histological examination. Results show that the vaccine in its therapeutic dose, at 3 times its therapeutic concentration, and its individual components did not cause death or behavioral or biological changes, including any abnormalities in whole-body or organ weights, and tissue damage. These results support the safety of ConvitVax with minimal to no side-effects.
format	article
author	María A. Duarte C. Jeismar M. Carballo O. Yetsenia M. De Gouveia Angie García Diana Ruiz Teresa Gledhill Eglys González-Marcano Ana F. Convit
author_facet	María A. Duarte C. Jeismar M. Carballo O. Yetsenia M. De Gouveia Angie García Diana Ruiz Teresa Gledhill Eglys González-Marcano Ana F. Convit
author_sort	María A. Duarte C.
title	Toxicity evaluation of ConvitVax breast cancer immunotherapy
title_short	Toxicity evaluation of ConvitVax breast cancer immunotherapy
title_full	Toxicity evaluation of ConvitVax breast cancer immunotherapy
title_fullStr	Toxicity evaluation of ConvitVax breast cancer immunotherapy
title_full_unstemmed	Toxicity evaluation of ConvitVax breast cancer immunotherapy
title_sort	toxicity evaluation of convitvax breast cancer immunotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/461a597176ad4ecb8e80b3aeab115e68
work_keys_str_mv	AT mariaaduartec toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT jeismarmcarballoo toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT yetseniamdegouveia toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT angiegarcia toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT dianaruiz toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT teresagledhill toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT eglysgonzalezmarcano toxicityevaluationofconvitvaxbreastcancerimmunotherapy AT anafconvit toxicityevaluationofconvitvaxbreastcancerimmunotherapy
_version_	1718379700802289664

Toxicity evaluation of ConvitVax breast cancer immunotherapy

Ejemplares similares